Trials
1 active
2 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “PST-611 is a naked plasmid DNA encoding human transferrin administered into the ciliary muscle”In the company’s words, NCT07705568 on ClinicalTrials.gov
- Tested for
- Geographic Atrophy, Age - Related Macular Degeneration (AMD)
- Main trialPhase 2
- “The goals of this interventional study are (1) to evaluate the safety and tolerability of multiple doses of PST-611 in men and women over the age of 65 with geographic atrophy secondary to age-related macular degeneration and (2) to assess efficacy of multiple doses of PST-611 by assessing retinal morphology and visual function changes over time. Participants will: * receive one dose every 20 weeks, for a total of 3 doses. * will be followed up for a total of 52 weeks following the first PST-611 dose.”In the company’s words, NCT07705568 on ClinicalTrials.gov
Other drugs for Geographic Atrophy
- TinlarebantBelite Bio, Inc · Phase 3
- VonaprumentAnnexon, Inc. · Phase 3
- CemdisiranRegeneron · Phase 3
- PozelimabRegeneron · Phase 3
- BevemipretideMighty Therapeutics Inc. · Phase 2/3
- JNJ-81201887Johnson & Johnson (Janssen) · Phase 2/3
Coming up1
- Jun 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Jun 2028 | An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy | |
| Phase 1Completed | 7 Apr 2026 | A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026